S. M. Gasanova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
S. M. Gasanova has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- A. D. Sandzhigoriaeva
Pirogov Russian National Research Medical University (Pirogov University)
2 shared publications - A. V. Uyutnova
Pirogov Russian National Research Medical University (Pirogov University)
2 shared publications - R. F. Safina
Pirogov Russian National Research Medical University (Pirogov University)
2 shared publications - S. A. Mikailova
Pirogov Russian National Research Medical University (Pirogov University)
2 shared publications - A. A. Belousova
Pirogov Russian National Research Medical University
1 shared publication - Aishat A. Udagova
Endocrinology Research Centre
1 shared publication
Latest Publications
- Open Access
- 15 July 2026
- Published by Arterialnaya Gipertenziya in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
- Vol. 32 (2) , 233-240
Diagnostic challenges of primary aldosteronism in a patient with chronic kidney disease and resistant arterial hypertension: a case report
Primary aldosteronism is a common cause of secondary arterial hypertension; however, its recognition may be substantially complicated by concomitant chronic kidney disease. Altered regulation of the renin-angiotensin- aldosterone system (RAAS), the effects of antihypertensive therapy, and the absence of typical laboratory features may create an atypical diagnostic profile and delay diagnosis. This article presents a clinical case of primary aldosteronism in a young patient with chronic kidney disease and resistant arterial hypertension, characterized by the absence of hypokalemia and by non-suppressed renin at the initial evaluation. After confirmatory testing and withdrawal of therapy affecting the RAAS, adrenalectomy was performed, and morphological and immunohistochemical examination confirmed an aldosterone-producing adenoma. This case illustrates the limitations of standard screening criteria and highlights the need for comprehensive interpretation of clinical, laboratory, and morphological findings when primary aldosteronism is suspected in patients with chronic kidney disease.
- 15 July 2026
- Published by Arterialnaya Gipertenziya in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
- Vol. 32 (2) , 233-240
Open AccessDiagnostic challenges of primary aldosteronism in a patient with chronic kidney disease and resistant arterial hypertension: a case report
Primary aldosteronism is a common cause of secondary arterial hypertension; however, its recognition may be substantially complicated by concomitant chronic kidney disease. Altered regulation of the renin-angiotensin- aldosterone system (RAAS), the effects of antihypertensive therapy, and the absence of typical laboratory features may create an atypical diagnostic profile and delay diagnosis. This article presents a clinical case of primary aldosteronism in a young patient with chronic kidney disease and resistant arterial hypertension, characterized by the absence of hypokalemia and by non-suppressed renin at the initial evaluation. After confirmatory testing and withdrawal of therapy affecting the RAAS, adrenalectomy was performed, and morphological and immunohistochemical examination confirmed an aldosterone-producing adenoma. This case illustrates the limitations of standard screening criteria and highlights the need for comprehensive interpretation of clinical, laboratory, and morphological findings when primary aldosteronism is suspected in patients with chronic kidney disease.
- 17 December 2025
- Published by Alfmed LLC in International journal of Innovative Medicine
- No. 3
Neuroinflammation as a central link in the pathogenesis of neurodegenerative diseases: molecular mechanisms, clinical correlates, and therapeutic perspectives
Neuroinflammation is regarded as a central mechanism driving the progression of neurodegenerative diseases, integrating age-associated inflammation, glial dysfunction, blood–brain barrier disruption, mitochondrial stress, and systemic factors. Activation of microglia and astrocytes, involvement of the NLRP3 inflammasome, dysregulation of TREM2 signaling, disturbances in iron and lipid metabolism, as well as the influence of the microbiota and metabolic comorbidities together form a self-sustaining pathological network that exacerbates neuronal loss in Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and multiple sclerosis. Emerging therapeutic strategies include modulation of microglia, inhibition of inflammasome-related cascades, epigenetic approaches, and nanotechnology-based delivery systems for anti-inflammatory compounds; however, their clinical efficacy remains limited. A deeper understanding of the architecture of neuroinflammation opens avenues for the development of targeted and personalized interventions.
- 17 December 2025
- Published by Alfmed LLC in International journal of Innovative Medicine
- No. 3
Neuroinflammation as a central link in the pathogenesis of neurodegenerative diseases: molecular mechanisms, clinical correlates, and therapeutic perspectives
Neuroinflammation is regarded as a central mechanism driving the progression of neurodegenerative diseases, integrating age-associated inflammation, glial dysfunction, blood–brain barrier disruption, mitochondrial stress, and systemic factors. Activation of microglia and astrocytes, involvement of the NLRP3 inflammasome, dysregulation of TREM2 signaling, disturbances in iron and lipid metabolism, as well as the influence of the microbiota and metabolic comorbidities together form a self-sustaining pathological network that exacerbates neuronal loss in Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and multiple sclerosis. Emerging therapeutic strategies include modulation of microglia, inhibition of inflammasome-related cascades, epigenetic approaches, and nanotechnology-based delivery systems for anti-inflammatory compounds; however, their clinical efficacy remains limited. A deeper understanding of the architecture of neuroinflammation opens avenues for the development of targeted and personalized interventions.
- 17 December 2025
- Published by Alfmed LLC in International journal of Innovative Medicine
- No. 3
Nootropics: effects on brain plasticity and cognitive functions
Nootropics represent a heterogeneous group of substances that affect cognitive functions primarily through modulation of neuroplasticity. Classic agents improve neuronal metabolism and, in experimental models, increase neurotrophin levels, but their clinical efficacy in dementia and other cognitive disorders remains moderate. Psychostimulants provide short-term improvement in attention and performance; however, they do not strengthen long-term plasticity and may adversely affect the developing brain. Herbal and nutraceutical agents exert mild and delayed effects, predominantly manifesting in individuals with mild cognitive complaints or deficits. Despite growing interest in pharmacological cognitive enhancement, convincing evidence of a clinically meaningful improvement in cognitive functions in healthy individuals is lacking, whereas the strongest effects on neuroplasticity continue to be demonstrated by non-pharmacological interventions.
- 17 December 2025
- Published by Alfmed LLC in International journal of Innovative Medicine
- No. 3
Nootropics: effects on brain plasticity and cognitive functions
Nootropics represent a heterogeneous group of substances that affect cognitive functions primarily through modulation of neuroplasticity. Classic agents improve neuronal metabolism and, in experimental models, increase neurotrophin levels, but their clinical efficacy in dementia and other cognitive disorders remains moderate. Psychostimulants provide short-term improvement in attention and performance; however, they do not strengthen long-term plasticity and may adversely affect the developing brain. Herbal and nutraceutical agents exert mild and delayed effects, predominantly manifesting in individuals with mild cognitive complaints or deficits. Despite growing interest in pharmacological cognitive enhancement, convincing evidence of a clinically meaningful improvement in cognitive functions in healthy individuals is lacking, whereas the strongest effects on neuroplasticity continue to be demonstrated by non-pharmacological interventions.